Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The Patriots released Antonio Brown only 11 days after signing the wide receiver.Sportsread more
The Wall Street Journal's report came as a top Ukraine official said President Donald Trump "is looking" for Ukraine officials to investigate business dealings of Biden's son...Politicsread more
A tour bus carrying Chinese-speaking tourists crashed near a national park in southern Utah, killing at least four people and critically injuring up to 15 others, authorities...U.S. Newsread more
Gun maker Colt announced Thursday that it will halt its production of AR-15 rifles for civilian sales, but the news might not be as exciting for gun control advocates as it...Guns and Weaponsread more
As thousands of people across the world participate in the Global Climate Strike, several Democratic presidential candidates have shared how they will take aggressive action...Scienceread more
With "tariff man" President Trump waging a tariff war and Democratic candidates pushing against big international deals, free trade has become politically homeless, writes...2020 Electionsread more
study (July 10)@ (Corrects July 10 story to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)
July 10 (Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.
Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market.
Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.
GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with fewer potentially toxic side effects.
The study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults with the HIV-1 virus who switched to the regimen from at least a triple combination containing Gilead Sciences' Descovy, the British company's HIV drugs division ViiV said.
ViiV also said adults who used Dovato did not develop any resistance to the treatment.
GSK already has a two-drug regimen Juluca on the market, but only for HIV patients that have received prior treatment.
Pfizer Inc and Shionogi & Co Ltd also have small stakes in ViiV, which accounted for about 39% of GSK's group operating profit last year, according to UBS analysts.
The HIV-1 category has the most widespread strains of the virus, which severely affects the body's immune system. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)